Barely Significant
← all excerpts

SingleNucleotide Polymorphisms as Biomarkers of Mepolizumab and Benralizumab Treatment Response in Severe Eosinophilic Asthma.

Int J Mol Sci · 2024 · PMC11311889 · PMID 39125709

Europe PMCDOI
1
hedged sentence
0.0730
closest p · 1.5× alpha
0.0730
boldest claim

The sentences

showed a trendp = 0.073so close (0.05 < p ≤ 0.1)
Predictors of Treatment Response Using the Exacerbation Reduction Criterion In the bivariate analysis, the variable that showed a trend towards a reduction in exacerbations was the absence of exacerbations in the previous year ( p = 0.073) ( Table S22 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.